anterior cruciate ligament rupture
Conditions
Interventions
experimental group:non-surgical treatment
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
8 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Aged 8-45 years; 2. Complete rupture of unilateral anterior cruciate ligament (ACL) (with/without partial meniscus tear); 3. The history of ACL injury should not be more than 2 months before enrollment; 4. Complete rupture of the ACL as determined by clinical examination and MRI; 5. Activity level scale 5-9 (Tegner activity score); 6. Degeneration of knee joint < KL II degree intraoperative cartilage injury < ICRS III degree; 7. The reason for the rupture of the anterior cruciate ligament is sports trauma.; 8. Complete rupture of the ACL meets the MRI indications: (1) The signal changes, deforms, and thickens on imaging, and is completely broken but not separated; (2) There is no sagging and separation of the broken ends; (3) The synovial image is continuous; 9. The physical examination of complete ACL rupture meets the following indications: (1) Lachman (-) or ADT (-) has one of them; (2) Or both are slightly loose, and the slack is not more than 10mm; (3) Vertical Leg position ADT (-) or slack < 5 mm.
Exclusion criteria
Exclusion criteria: 1. Intra-articular injection and/or physical therapywere used in the previous 12 months; 2. Those who broke again after surgery and underwent knee surgery in other hospitals; 3. Previous knee surgery (except diagnostic arthroscopy); 4. Active infection of the knee joint within the past 12 months; 5. Informed consent cannot be given; 6. History of knee gout; 7. Include one or more of the following knee-related injuries: Bicompartmental wide meniscectomy; Total collateral ligament rupture; Full thickness cartilage lesions; 8. Unstable meniscus tears requiring repair or post-operative changes in rehabilitation; 9. History of rheumatoid arthritis or similar rheumatic diseases; 10. The discovery of rheumatoid arthritis, rheumatoid arthritis pigment villonodular synovitis and other joint diseases during the postoperative follow-up period may impair the ability to participate in the study; 11. Unable to speak/understand the research content, lack of autonomy, unable to walk, or unable to participate in follow-up; 12. Participate in any drug trials during and after the disease; 13. Any other medical condition that considers the longest survival time to be less than 2 years; 14. Immunodeficiency or HIV positive; 15. Illegal drug use or chronic alcoholism or total daily alcohol intake > 50 g/d; 16. Pregnancy/planning pregnancy; 17. There are contraindications such as current or previous history of neurological disease, cerebrovascular and serious cardiovascular disease, including coronary heart disease (angina pectoris, myocardial infarction, coronary angiogenesis process or abnormal electrocardiogram Q wave appearance), Stroke (ischemic or hemorrhagic, including transient ischemic attack), peripheral arterial disease diagnosed by angiography; 18. No imaging diagnosis; 19. History of deep vein thrombosis (DVT) or blood system; 20. There is a systemic disease that affects physical function, or there is any other condition or treatment that prevents the completion of the trial, including patients with metal devices or movement disorders.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Lysholm score; | — |
Primary
| Measure | Time frame |
|---|---|
| International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form 2000;Magnetic Resonance Imaging; | — |
Countries
China
Contacts
Public ContactYu Jiakuo
Outcome results
None listed